EP08.02-012 Real-world Analysis of the Efficacy and Safety of lorlatinib in Patients with ALK-Positive Non-small Cell Lung Cancer in Korea

Anaplastic lymphoma kinase (ALK) translocation is a targetable driver mutation in non-small cell lung cancer (NSCLC). Lorlatinib, a next-generation central nervous system-penetrant ALK tyrosine kinase inhibitor (TKI), is approved to treat TKI-refractory ALK-positive NSCLC based on results from previous studies. This study was aimed to report on the efficacy and safety of lorlatinib in real-world practice of Korea.